According to FINRA, Nickolay V. Kukekov was assessed a deferred fine of $5,000 and suspended for 30 days for engaging in outside business activities without providing prior written notice to his member firm.
The findings revealed that Kukekov engaged in business activities outside the scope of his relationship with the firm through a publicly traded company that develops stem cell therapies. Kukekov did not provide any notice to the firm until it discovered that he was serving as a director of the company through a review of his email. Thereafter, Kukekov requested approval of the outside business activity, which his firm granted.
Further, Kukekov engaged in an outside business activity through a second company developing treatments for a degenerative brain disease. Kukekov informed prospective investors of the second company that he had accepted a transitional role as its CEO, a position that the second company later formalized. The firm later discovered Kukekov's participation in outside business activities through the second company and discharged him.
FINRA rules require registered persons to provide prior written notice to their member firm before engaging in any business activity outside the scope of their relationship with the firm. This requirement serves several important purposes. First, it allows firms to evaluate whether the outside activity presents conflicts of interest with the person's responsibilities to the firm or its customers. Second, it enables firms to determine whether the activity might interfere with the person's ability to fulfill their obligations to the firm. Third, it allows firms to assess whether the outside activity might create reputational risks for the firm or confusion about whether the activity is connected to the firm.
The requirement for prior written notice is straightforward and not unduly burdensome—it simply requires registered persons to inform their firms about outside activities before engaging in them. The fact that Kukekov failed to provide this notice for not just one but two separate companies demonstrates either a lack of understanding of this basic requirement or a deliberate choice to avoid firm oversight of his outside activities.
The nature of the outside activities makes the violations particularly concerning. Kukekov was serving as a director of a publicly traded stem cell therapy company and later as CEO of a company developing treatments for degenerative brain disease. These are significant leadership roles in healthcare-related companies that could involve securities transactions, fundraising, and interactions with investors. The potential for conflicts of interest or confusion about whether Kukekov was acting on behalf of his firm when engaging in these activities was substantial.
The firm's discovery of the first outside activity through email review, rather than through proper disclosure by Kukekov, indicates that he was conducting these activities without transparency. Although the firm granted approval after discovering the first activity, Kukekov's later engagement with the second company without disclosure ultimately resulted in his termination from the firm.
The 30-day suspension and $5,000 fine appropriately address these violations. The case serves as a reminder that the prior written notice requirement for outside business activities is a fundamental obligation that registered persons must meet. The requirement exists to protect both firms and customers by ensuring that all outside activities are subject to appropriate evaluation and oversight.
Investors should be aware that registered representatives may engage in outside business activities with their firm's approval, but such activities must be properly disclosed. When representatives engage in undisclosed outside activities, it raises questions about what else they might be concealing and whether they are meeting their obligations to their firm and customers.
